Genetically engineered live-attenuated Middle East respiratory syndrome coronavirus viruses confer full protection against lethal infection
J Gutiérrez-Álvarez, JM Honrubia… - MBio, 2021 - Am Soc Microbiol
There are no approved vaccines against the life-threatening Middle East respiratory
syndrome coronavirus (MERS-CoV). Attenuated vaccines have proven their potential to …
syndrome coronavirus (MERS-CoV). Attenuated vaccines have proven their potential to …
[HTML][HTML] Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models
Y Wang, J Sun, A Zhu, J Zhao, J Zhao - Journal of thoracic disease, 2018 - ncbi.nlm.nih.gov
Middle East respiratory syndrome (MERS) is a highly lethal respiratory disease caused by a
novel betacoronavirus (MERS coronavirus, MERS-CoV). Since its first emergence in 2012 …
novel betacoronavirus (MERS coronavirus, MERS-CoV). Since its first emergence in 2012 …
Cellular and humoral immunogenicity of a candidate DNA vaccine expressing SARS-CoV-2 spike subunit 1
KA Alluhaybi, RH Alharbi, RY Alhabbab, ND Aljehani… - Vaccines, 2021 - mdpi.com
The urgent need for effective, safe and equitably accessible vaccines to tackle the ongoing
spread of COVID-19 led researchers to generate vaccine candidates targeting varieties of …
spread of COVID-19 led researchers to generate vaccine candidates targeting varieties of …
Cross-protection against MERS-CoV by prime-boost vaccination using viral spike DNA and protein
J Choi, J Goo, E Yang, DI Jung, S Lee, S Rho… - Journal of …, 2020 - Am Soc Microbiol
Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe respiratory
illness and has a high mortality of∼ 34%. However, since its discovery in 2012, an effective …
illness and has a high mortality of∼ 34%. However, since its discovery in 2012, an effective …
[HTML][HTML] 新型冠状病毒疫苗研究策略分析
杨利敏， 田德雨， 刘文军 - 生物工程学报, 2020 - cjb.ijournals.cn
新型冠状病毒(SARS-CoV-2) 是一种可引起人新型冠状病毒肺炎(COVID-19)
的新发呼吸道病原体, 与重症急性呼吸道综合症冠状病毒(SARS-CoV) 和中东呼吸综合征冠状 …
的新发呼吸道病原体, 与重症急性呼吸道综合症冠状病毒(SARS-CoV) 和中东呼吸综合征冠状 …
An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies
N Zhang, J Shang, C Li, K Zhou, L Du - Expert review of vaccines, 2020 - Taylor & Francis
ABSTRACT Introduction Middle East respiratory syndrome coronavirus (MERS-CoV) causes
high mortality in humans. No vaccines are approved for use in humans; therefore, a …
high mortality in humans. No vaccines are approved for use in humans; therefore, a …
Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice
H Kato, M Takayama-Ito, I Iizuka-Shiota, S Fukushi… - PLoS …, 2019 - journals.plos.org
Middle East respiratory syndrome-coronavirus (MERS-CoV) is an emerging virus that
causes severe disease with fatal outcomes; however, there are currently no approved …
causes severe disease with fatal outcomes; however, there are currently no approved …
[HTML][HTML] Newly emerging human coronaviruses: animal models and vaccine research for SARS, MERS, and COVID-19
P Lee, DJ Kim - Immune Network, 2020 - ncbi.nlm.nih.gov
The recent emergence of the novel coronavirus (CoV) or severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) poses a global threat to human health and economy. As of …
coronavirus-2 (SARS-CoV-2) poses a global threat to human health and economy. As of …
[HTML][HTML] SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines
SGD León-Rodríguez, B Hernández-Rico… - Boletín médico del …, 2020 - scielo.org.mx
Since the emergence of the new severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) in China at the end of 2019, when its characteristics were practically unknown, one …
CoV-2) in China at the end of 2019, when its characteristics were practically unknown, one …
Nucleic acid vaccine candidates encapsulated with mesoporous silica nanoparticles against MERS-CoV
I Almansour, BR Jermy - Human Vaccines & Immunotherapeutics, 2024 - Taylor & Francis
Middle East respiratory coronavirus (MERS-CoV) is a newly emergent, highly pathogenic
coronavirus that is associated with 34% mortality rate. MERS-CoV remains listed as priority …
coronavirus that is associated with 34% mortality rate. MERS-CoV remains listed as priority …